Shuttle Pharmaceuticals

IN THE PRESS

Business

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024

·

5 min read

BioCapital

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

April 3, 2024

·

2 min read

BioCapital

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

March 5, 2024

·

2 min read

Deals

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

February 13, 2024

·

5 min read

Drug Development

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

January 8, 2024

·

4 min read

BioCapital

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

December 11, 2023

·

5 min read

BioCapital

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

November 30, 2023

·

2 min read

Business

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

November 14, 2023

·

6 min read

BioCapital

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

October 10, 2023

·

1 min read

BioCapital

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

September 25, 2023

·

3 min read

JOBS